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TO THE EDITOR
Staphylococcus aureus is a leading
cause of human skin infections, con-
tributing to disease in both healthy and
immunocompromised individuals, also
complicating burn and surgical wound
sites and lesions of atopic dermatitis
(Lowy, 1998; Ong and Leung, 2010).
Host defense against staphylo-
coccal skin infection is multifaceted,
relying on local immunological control
through TH17 and IL-1b–driven recruit-
ment of neutrophils in addition to the
protective actions of antimicrobial pep-
tides and physical properties of the
cutaneous barrier (Miller and Cho,
2011). Pathogen virulence in staphylo-
coccal skin infection is likewise multi-
factorial (Weidenmaier et al., 2010),
relying in part on the action of
a-hemolysin, a pore-forming cytotoxin
secreted by almost all strains of
S. aureus. Hla is required for dermone-
crotic changes during infection, also
contributing to abscess size (Kennedy
et al., 2010). Immunization strategies
targeting Hla protect against dermone-
crosis (Kennedy et al., 2010); however,
the molecular mechanism by which the
toxin causes pathological disturbance
of the epithelial barrier is ill under-
stood.
We recently identified the zinc-
dependent metalloprotease ADAM10
as the cellular receptor for Hla
(Wilke and Bubeck Wardenburg,
2010). ADAM10 regulates epithelial
function through its ability to cleave
E-cadherin, severing the protein-based
adherens junction tether between adja-
cent cells (Maretzky et al., 2005).
ADAM10 knockout mice exhibit
embryonic lethality (Hartmann et al.,
2002), whereas conditional skin knock-
out of ADAM10 during gestation or
in the postnatal epidermis results
in marked dysregulation of epithelial
differentiation and barrier function
(Weber et al., 2011). To examine the
contribution of ADAM10 to skin infec-
tion, we generated conditional knock-
out mice in which exon 3 of ADAM10
is flanked by loxP sites (Tian et al.,
2008), excised in the presence of a Cre
recombinase expressed under control
of the keratin 14 promoter (Vasioukhin
et al., 1999). Topical application of
tamoxifen to a 1-cm2 skin area for 5
days leads to localized ADAM10 geno-
mic excision (Supplementary Figure
S1a and b online), abrogating epider-
mal ADAM10 expression (Figure 1a,
ADAM10/). In contrast to litter-
mate controls, ADAM10/ mice did
not develop dermonecrotic lesions
following subcutaneous infection with
3107 colony forming units (CFUs) of
the epidemic S. aureus USA300/
LAC (Figure 1b and c). Abscess size
was reduced in ADAM10/ mice
(Figure 1d), however, lesional bacterial
recovery was unaltered (Supplementary
Figure S1c online).
The ability of ADAM10 to cleave
E-cadherin suggested that Hla may use
its receptor to cause epithelial barrier
injury, not merely to facilitate binding.
Toxin treatment of A431 keratinocytes
led to upregulation of cell-associated
metalloprotease activity measured in
a fluorogenic substrate assay; the
non-pore-forming HlaH35L mutant did
not elicit this response (Figure 1e).
Enhanced metalloprotease activity
correlated with E-cadherin cleavage,
detectable by immunoblot analysis of
E-cadherin precipitates from A431
lysates as the toxin-induced loss of
full-length protein and C-terminal frag-
ment (Ctf) accumulation produced by
ADAM10-dependent cleavage (Figure
1f). Ctf accumulation was also observed
in cultured primary keratinocytes upon
toxin treatment (Supplementary Figure
S1d online). These molecular events
occurred at subcytolytic concentrations
of Hla (10 mg per ml, data not shown),
wherein a disturbance of cell–cell inter-
actions in an A431 monolayer was
manifest as a loss of resistance to the
passage of an electrical current using
electrical cell–substrate impedance
sensing (Figure 1g).
These findings suggest that the
principal role of the toxin–receptor
complex may be to disrupt the epithelial
barrier. Within 24 hours following
S. aureus infection, loss of E-cadherinAbbreviations: CFU, colony forming unit; Ctf, C-terminal fragment
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surface expression in epidermal tissue
overlying the infection was evident in
control mice as compared with
ADAM10/ mice (Figure 1h). Inflam-
matory cell infiltration at the infection site
was similar in both control and
ADAM10/ mice (Figure 1i, upper,
arrows), however, epidermal loss was
apparent overlying the abscess site only
in control mice (Figure 1i, lower). To-
gether with CFU analysis, these results
indicate that the Hla–ADAM10 complex
does not markedly alter the host response
to infection or bacterial accumulation.
Epithelial injury induced by the toxin–
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Figure 1. ADAM10 mediates a-hemolysin-dependent epithelial injury. (a) Epidermal expression of ADAM10 visualized by anti-mouse ADAM10
immunohistochemical staining of tissues derived from ADAM10/– mice, in which topical treatment with tamoxifen (TAM, dissolved in ethanol, 1 mg per mouse
per day for 5 days, applied to a 1-cm2 area) induces loss of ADAM10 expression through Cre recombinase-mediated excision of ADAM10loxP alleles or
control mice treated with ethanol alone. (b) Dermonecrosis area recorded from control mice that received topical treatment with vehicle alone (n¼ 13) or TAM
(n¼8), or ADAM10/ mice treated with TAM (n¼ 13) followed by subcutaneous infection at the site of vehicle or TAM application with 3 107 S. aureus
USA300/LAC, *Po0.001. (c) Image of mice treated as described in b and d. (d) Abscess area recorded from mice detailed in b where ‘‘þ ’’ denotes Po0.05.
Area in b and d was calculated based on the formula A¼ [p/2] lengthwidth, where error bars represent SEM. All animal studies were reviewed, approved,
and supervised by the Institutional Animal Care and Use Committee at the University of Chicago. (e) Cell-associated metalloprotease activity measured in
A431 keratinocytes following treatment with 10 mg ml1 (300 nM) active Hla or the non-toxigenic mutant HlaH35L at the time points indicated. Activity was
quantified by detection of the product derived from cleavage of the fluorogenic peptide substrate Mca-PLAQAV-Dpa-RSSSR-NH2 (10 mM, R&D Systems,
Minneapolis, MN) diluted in 25 mM Tris, pH 8.0. (f) Immunoblot analysis of full-length (Fl) E-cadherin and accumulation of the C-terminal cleavage fragment
(Ctf) following treatment of A431 cells with controls DMSO and ionomycin compared with 10 mg ml1 HlaH35L or Hla over the time course indicated.
(g) Electrical cell–substrate impedance sensing (Applied Biophysics, Troy, NY) recordings of A431 monolayers treated with phosphate-buffered saline (PBS;
black), the HlaH35L mutant (10 mg ml
1, red), or active Hla (10mg ml1, blue). (h) E-cadherin (green) immunofluorescence microscopy analysis of tissue from
control or ADAM10/ mice 24 hours following infection with 3 107 S. aureus delivered by subcutaneous route. Nuclei (blue) are stained with the fluorescent
DNA stain 40-6-diamidino-2-phenylindole. (i) Hematoxylin and eosin staining of tissues from mice treated as described in h, shown at 4 (upper) with a
20 image of the highlighted area (lower). The site of infection and inflammatory cell recruitment is marked by yellow arrows. Bars in (a)¼ 50mm, (h)¼10 mm,
(i)¼ 100mm. MW, molecular weight.
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receptor complex likely contributes to
tissue edema and increased lesional size
observed in control mice (Figure 1d).
These data raised the possibility that
an enzymatic inhibitor of ADAM10
may protect the epithelium. Mice
receiving systemic treatment with the
ADAM10 inhibitor GI254023X (Ludwig
et al., 2005; 200 mg kg1 per day, 5
days) did not demonstrate dermonecro-
tic lesions following infection com-
pared with mice treated with the
DMSO vehicle (Figure 2a). Topical
application of GI254023X also pre-
vented skin breakdown (Figure 2b,
100 mg kg1 per day, 5 days). Both
routes of treatment led to a reduction
in abscess size (data not shown).
In vitro GI254023X treatment preserved
E-cadherin expression and epithelial
barrier function in toxin-treated A431
cells (Figure 2c and d).
These studies provide insight
into pathogenesis of staphylococcal
skin infection demonstrating a genetic
requirement for ADAM10 expression to
mediate epithelial barrier injury, which
to our knowledge is previously unre-
ported. The Hla–ADAM10 complex
thereby disables the most innate host
defense of the skin. These findings
extend recent observations that demon-
strate a role for ADAM10 in Hla-mediated
injury to the lung epithelium and
vascular endothelium (Inoshima et al.,
2011; Powers et al., in press), defin-
ing a generalized principle of toxin
action in which Hla uses its cellular
receptor as a means to bind host cells
and cause barrier injury. As ADAM10
cleaves multiple cellular substrates, it is
of considerable interest to now under-
stand the potential role of these proteins
in staphylococcal disease pathogenesis.
These observations have important
implications for S. aureus skin disease.
First, Hla may facilitate an initial breach
of intact skin to permit pathogen inva-
sion. Second, ADAM10 polymorphisms
that alter toxin binding or enzymatic
activity may exist, impacting suscept-
ibility to infection. Finally, in disease
states characterized by a compromise
of epithelial barrier function such as
atopic dermatitis, S. aureus may poten-
tiate or incite barrier disruption, con-
tributing to pathology and facilitating
niche establishment. Indeed, S. aureus
is the most common bacterial pathogen
complicating atopic dermatitis lesions
(Ong and Leung, 2010). Studies impli-
cating ADAM10 in atopic dermatitis
pathogenesis (Maretzky et al., 2008),
together with our observations, suggest
that the Hla–ADAM10 interaction may
contribute to epidermal pathology over
a continuum of staphylococcal skin
disease ranging from acute infection to
chronic barrier insults. Therapies im-
pacting ADAM10 activity may therefore
demonstrate broad clinical utility.
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Figure 2. An ADAM10 inhibitor protects against Hla-induced injury. (a) Dermonecrosis area recorded
from wild-type mice that received a 5-day course of once-daily intraperitoneal injection with vehicle
alone (DMSO) or the ADAM10 inhibitor GI254023X (200 mg kg1 per day, OKeanos, Beijing, China),
followed by subcutaneous infection with 3 107 S. aureus USA300/LAC (n¼10 mice per group).
(b) Dermonecrosis area recorded from wild-type mice that received a 5-day course of once-daily topical
application with vehicle alone (DMSO) or the ADAM10 inhibitor GI254023X (100 mg kg1 per day),
followed by subcutaneous infection with 3 107 S. aureus USA300/LAC (n¼10 mice per group),
þPo0.05 and *Po0.001 in a and b. (c) Immunoblot analysis of full-length (Fl) E-cadherin and
accumulation of the C-terminal cleavage fragment (Ctf) following pre-treatment of A431 cells with DMSO
or GI254023X, then exposed to 10mg ml1 Hla for the time periods indicated. (d) Electrical cell–substrate
impedance sensing recordings of A431 monolayers treated with phosphate-buffered saline (PBS; black),
or Hla (10 mg ml1) following pre-treatment with control DMSO (blue) or GI254023X (20 mg ml1, red).
MW, molecular weight.
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Thymic Peptides Differentially Modulate Human Hair
Follicle Growth
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TO THE EDITOR
Topical preparations containing thymus-
derived protein extracts have long been
claimed to stimulate human hair growth
(Renner et al., 1986; Sawaya and Sha-
piro, 2000), but there is still no convin-
cing evidence available that they really
modulate human hair growth. Despite
their historical name, most thymic pep-
tides (TPs), such as thymosin b4 (TB4),
prothymosin alpha (PTMA), and thymulin
(TYL), are much more widely distributed
than in the thymic epithelium where they
were first identified (Kato et al., 1981;
Moll et al., 1996; Folch et al., 2010;
Supplementary Information S1 online).
The PTMA gene is prominently expressed
in many rodent tissues (Moll et al., 1996),
including fetal murine hair follicles (HFs).
PTMA is involved in many cellular
processes such as apoptosis, chromatin
remodeling, and transcriptional regula-
tion (reviewed in Hannappel and Huff
(2003)); Supplementary Information S1
online). TYL has been claimed to be
thymus specific, although TYL immuno-
reactivity has also been reported in
murine epidermis and skin appendages
(Kato et al., 1981) and in murine spleen
(Folch et al., 2010). Interactions between
TYL and the neuroendocrine system have
been reported to lead to a release of
prolactin, thyrotropin, and ACTH (Hadley
et al., 1997; Brown et al., 1998). As these
neurohormones are well appreciated as
regulators of human HF growth, cycling,
and pigmentation (Paus, 2011), it is
particularly interesting to investigate
TYL in a hair research context.
Topically applied TB4 reportedly
enhances hair growth in rats and mice
and stimulates early differentiation of
rat vibrissae epithelial progenitor cells
(Philp et al., 2004), whereas it is un-
known whether TB4 impacts on human
hair growth. Therefore, we wished to
clarify in the current study whether
human scalp HFs express any TPs, and
whether selected TPs exert measurable
effects on human scalp HFs in organ
culture (Kloepper et al., 2010).
Abbreviations: HF, hair follicle; IRS, inner root sheath; ORS, outer root sheath; PTMA, prothymosin alpha;
TB4, thymosin b4; TP, thymic peptide; TYL, thymulin
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